Please ensure Javascript is enabled for purposes of website accessibility
Dave Williamson

Dave Williamson


The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...

Recent articles


Market Fallout From the EPA's Rush Decision

The Environmental Protection Agency is moving quickly to finalize 2025 emission standards.

Hertz Blinks First With Car Rental Marching Toward Abyss

Hertz's deal with Lyft highlights the direction the industry must move in to survive.

Welcome to Prime Time, Driverless Cars

The Alphabet vs. Apple battle, the Tesla Model X release, and the VW diesel scandal highlight an industry at an inflection point.

3 Key Developments for Autonomous Cars

The mobility revolution moves ahead full steam.

Cheap Car Rental Stocks Are a Bad Idea

This is a business model prime for disruption and will bring value-seeking investors nothing but misery.

Top Stocks to Invest in Autonomous Cars

These two hidden investment ideas have tremendous upside potential.

The Self-Driving Car and the Future of Mobility

A revolution in how we travel is nearly upon us.

5 Investing Lessons from NFL Free Agency

Winning NFL roster construction has direct parallels to smart investing

After Apple: Tech's Takeover of Healthcare Officially Begins

Ebola is spreading, new diabetes and obesity drugs, and Apple and Google move into healthcare, because this is where the money is.

Ebola Vaccine and Inhaled Insulin Incoming

Biotech partnerships, an IPO that wasn't, and how big data is fighting Ebola.

3 Key Takeaways from Biogen Idec Inc Stock's Earnings Annihilation

An executive summary of a monster quarter

Herbalife Says "I Think I-Cahn" as Short-Sellers Go "Ack, Man"

Pershing Square's Bill Ackman's scathing presentation sends Herbalife shares soaring

ISIS Pharmaceuticals, Inc. is The Best Stock Today

The Motley Fool readers made their voices heard as it wins a 32 stock tournament

Why the Market is Wrong about Johnson & Johnson

Todays sell-off at odds with second quarter results and guidance update

1 Special Situation Dividend Stock: Snatch Up of Stay Away?

Is the Theravance split may be a buying opportunity or a dividend chasing mistake?

Should Dividend Investors Keep or Eject Bristol-Myers Squibb Co?

World Cup mania and dividend stocks collide

Is Europe Igniting Eli Lilly's Comeback?

The CHMP recommends approval for Lantus biosimilar insulin

A Big Pharma Sex Tape Compounds China Woes

GlaxoSmithKline's troubles in China just won't go away

How Obamacare Exchange Innovation Can Go Wrong

The tech industy's disruptive model may not work for insurance customers

1 Key Question Remains after MannKind's Giant Leap

After FDA approval, now comes the hard part

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.